Considering the promising results and efficacy of icotinib, this study aimed to investigate an effective prognostic scoring system to predict the one-year PFS for advanced NSCLC patients with EGFR mutations treated with icotinib as an EGFR-TKI targeted therapy. Here, EGFR is linked to non-small cell lung carcinoma.